A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
ALLERGIC ASTHMA
Interventions
DRUG

ANTI-IGE THERAPY (XOLAIR)

Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Children's Hospital of The King's Daughters

OTHER